Kasra Pakdaman

Kasra Pakdaman

Auto-generated profile, based on publicly available information

Kasra Pakdaman

School of Nursing and Midwifery, Mazandaran University of Medical Sciences, Sari, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2025 in Annals of Medicine
Verified
Journal Article
Open access
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
KPKimia Pakdaman
Kimia Pakdaman
ZMZahra Maleki
Zahra Maleki
SSSoroush Soraneh
Soroush Soraneh
FCFatemeh Rezaei Chegini
Fatemeh Rezaei Chegini
PEPouyan Ebrahimi
Pouyan Ebrahimi
Haemorrhoidal disease (HD) is one of the most common anorectal disorders globally, significantly impacting individuals' quality of life and productivity. Despite its importance, global prevalence remains unclear due to limited population-specific studies. This study aimed to systematically assess the global prevalence of HD through a systematic review and meta-analysis. We conducted a systematic review and meta-analysis by searching PubMed, Scopus, Embase, Web of Science, and Google Scholar up to March 31, 2025, without language restrictions. Studies reporting prevalence of haemorrhoids in general, clinical, or high-risk populations were included. Exclusion criteria comprised studies lacking total sample size, focusing on other anorectal conditions, or using duplicate or insufficient data. Four independent reviewers extracted and appraised study quality using the Joanna Briggs Institute tool. The primary outcome was pooled point prevalence of HD, analyzed using a random-effects model with 95% confidence intervals (CIs). The study was registered in PROSPERO (CRD420251045600). From 6,312 records, 150 studies (210 datasets) comprising 8,960,338 individuals were included. The global pooled point prevalence was 25.92% (95% CI: 22.62-29.22). Lifetime prevalence was 27.19% (95% CI: 14.77-39.60), and one-year prevalence was 21.65% (95% CI: 14.33-28.97). Prevalence was higher in women (27.33%, 95% CI: 21.84-32.82) than in men, and highest in the African region 28.07% (95% CI: 15.34-40.79). Invasive diagnostic methods (28.05%, 95% CI: 23.86-32.26) yielded higher prevalence estimates than non-invasive methods. Also, factors showing associations with HD in unadjusted analyses include older age, obesity, pregnancy, diabetes, family history, constipation, and hypertension. HD remains a prevalent condition globally, with minor variation across regions. The burden is consistent regardless of socioeconomic context. Diagnostic method and population characteristics influence prevalence estimates. These findings underscore the importance of targeted prevention and early intervention strategies, especially for at-risk groups.

26 November 2025 in Cancer Reports
Verified
Journal Article
Open access
KPKimia Pakdaman
Kimia Pakdaman
AAAmirhossein Alizadeh‐Nodehi
Amirhossein Alizadeh‐Nodehi
ALAmir‐Hossein Lashkarbolouki
Amir‐Hossein Lashkarbolouki
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
KPKasra Pakdaman
Kasra Pakdaman
PEPouyan Ebrahimi
Pouyan Ebrahimi
Background: Cervical cancer (CC) remains the fourth most prevalent malignancy among women globally, with a disproportionate burden in low‐ and middle‐income countries, where it is often diagnosed at advanced or metastatic stages. Aims: Despite an increasing number of case reports and institutional studies on brain metastases (BMs) arising from CC, current understanding of their epidemiology, clinical presentation, and prognostic implications remains fragmented and lacks comprehensive synthesis. Methods: We executed a systematic and unrestricted search of five major databases, PubMed/Medline, Scopus, Embase, Web of Science, and Google Scholar, covering all records up to April 19, 2025. Studies were eligible for inclusion if they provided a clear report on the incidence of BMs among CC patients. The quality and risk of bias of the selected studies were independently appraised using the Joanna Briggs Institute (JBI) assessment criteria. For statistical analysis, we utilized STATA version 17, implementing random‐effects meta‐analytical models to estimate the aggregated incidence along with corresponding 95% confidence intervals (CIs). Results: A total of 17 studies encompassing 33 datasets were included in the final analysis. The global pooled incidence of BMs among cervical cancer patients was estimated at 0.65% (95% CI: 0.46–0.85). Incidence was highest in Turkey (1.83%, 95% CI: 0.91–2.75) and lowest in South Africa (0.22%, 95% CI: 0.0–0.47). Among histologic subtypes, neuroendocrine carcinoma exhibited the highest pooled incidence of BMs at 10.60% (95% CI: 0.0–21.63), followed by adenocarcinoma at 0.89% (95% CI: 0.14–1.64). The pooled mean survival time following the diagnosis of BMs was 6.80 months (95% CI: 5.08–8.52), while the mean interval from the initial cervical cancer diagnosis to the development of BMs was 28.15 months (95% CI: 24.27–32.03). Conclusion: Although BMs in cervical cancer are rare, they are associated with dismal survival outcomes and poor prognosis. These findings underscore the importance of vigilant surveillance in high‐risk patients and may inform the development of more targeted and effective therapeutic and preventive strategies.

27 December 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
KPKimia Pakdaman
Kimia Pakdaman
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
KPKasra Pakdaman
Kasra Pakdaman
BKBardia Karim
Bardia Karim
SSSaba Sahraian
Saba Sahraian
PEPouyan Ebrahimi
Pouyan Ebrahimi
Background Cervical cancer remains a major malignancy among women, with poor survival rates below 20% despite advances in care. Patients with cervical cancer are most likely to develop hematogenous metastases in the liver, followed by the lungs and bones. Although less commonly involved than other organs, the liver is associated with the poorest prognosis among metastatic sites. This study aims to estimate the global incidence of liver metastasis in cervical cancer patients and explore its clinicopathological characteristics. Methods This is a systematic review and meta-analysis conducted to assess the global incidence and clinicopathological characteristics of liver metastasis in cervical cancer patients. The review followed PRISMA guidelines, and a comprehensive search was performed in Embase, PubMed, Web of Science, Scopus, and Google Scholar up to February 28, 2025. Eligibility criteria included studies that explicitly reported the incidence of liver metastases following a diagnosis of cervical cancer, and provided data on both total cervical cancer cases and cases with liver metastases. Exclusion criteria were studies lacking clear incidence data, case reports, reviews, or studies not specific to cervical cancer. The pooled incidence was calculated using a random-effects model implemented in STATA version 17, based on raw proportions. Results were presented with 95% confidence intervals (CI), and heterogeneity was assessed using the I² statistic. Results Out of an initial 7508 articles identified across five databases, 11 studies (comprising 20 records) met the eligibility criteria and were included in the final analysis. The global pooled incidence of liver metastasis among cervical cancer patients was estimated at 1.88% (95% CI: 1.27–2.48). To explore variability among populations, we conducted subgroup analyses based on development indices. Countries with a very high Human Development Index (HDI) reported a higher incidence (2.12%, 95% CI: 1.40–2.84) than those with high (1.96%, 95% CI: 0.98–2.94) and medium (0.75%, 95% CI: 0.0–1.57) HDI levels. The incidence of liver metastasis in combination with metastases to other organs was nearly three times greater (1.76%, 95% CI: 0.99–2.53) than that of isolated liver metastasis. Furthermore, in a subgroup analysis based on histological subtype, the highest pooled incidence was observed in patients with cervical adenocarcinoma (2.36%, 95% CI: 1.35–3.37). Conclusion This meta-analysis demonstrates that while liver metastasis in cervical cancer is relatively rare, its occurrence appears more frequently in patients with advanced disease. These results underscore the need for routine liver screening in high-risk patients and support the refinement of therapeutic strategies.

2 March 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KPKimia Pakdaman
Kimia Pakdaman
AAAmirhossein Alizadeh-Nodehi
Amirhossein Alizadeh-Nodehi
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
ASAmir Morteza Soleimani
Amir Morteza Soleimani
SMSara Mohammadnia
Sara Mohammadnia
PEPouyan Ebrahimi
Pouyan Ebrahimi
The integration of immune checkpoint inhibitors with anti-angiogenic therapy has transformed the management of advanced malignancies. Atezolizumab (ATZ), a

21 July 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KPKimia Pakdaman
Kimia Pakdaman
ASAmin Esmaeilnia Shirvani
Amin Esmaeilnia Shirvani
KPKasra Pakdaman
Kasra Pakdaman
HNHossein-Ali Nikbakht
Hossein-Ali Nikbakht
MYMosua Yeminfroz
Mosua Yeminfroz
PEPouyan Ebrahimi
Pouyan Ebrahimi
Cervical cancer (CC) is a common and aggressive malignancy in women. The lung is its most frequent site of distant metastasis, yet the incidence and risk f

8 July 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
YHYi Huang
Yi Huang
AAAmirhossein Alizadeh-Nodehi
Amirhossein Alizadeh-Nodehi
KPKasra Pakdaman
Kasra Pakdaman
Cardiovascular diseases (CVDs) continue to be the leading cause of death worldwide, with dyslipidemia as one of their main risk factors. Nurse-led cardiac rehabilitation (NLCR) has been shown to improve the quality of life of cardiac patients. We aim to measure its effect on lipid levels. We conducted a systematic review and meta-analysis of clinical trials comparing NLCR with usual care. Major electronic databases and grey literature sources were searched through July 31, 2025. Eligible studies reported at least one lipid outcome, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). Risk of bias was assessed using RoB 2.0 for randomized controlled trials (RCTs) and ROBINS-I for non-RCTs. Random-effects models were used to calculate pooled standardized mean differences (SMDs) and mean differences (MDs) with 95% confidence intervals (CIs). Ten studies were included in the meta-analysis. NLCR was associated with a significant reduction in TG levels (SMD = - 0.19; 95% CI: -0.36 to - 0.02), corresponding to an absolute reduction of 8.38 mg/dL (MD = - 8.38; 95% CI: -13.82 to - 2.94). Changes in TC (MD = - 6.03 mg/dL; 95% CI: -14.57 to 2.51), LDL-C (MD = - 4.78 mg/dL; 95% CI: -9.89 to 0.33), and HDL-C (MD = 1.90 mg/dL; 95% CI: -2.30 to 6.10) did not reach statistical significance in the overall analysis. Subgroup analyses demonstrated a significant TG reduction among RCTs (MD = - 9.25 mg/dL; 95% CI: -14.84 to - 3.65). According to follow-up duration, studies with follow-up durations of ≤ 3 months showed a significant reduction in TC levels (MD = - 9.81 mg/dL; 95% CI: -14.13 to - 5.49), whereas studies with follow-up durations of > 3 months demonstrated a significant reduction in TG levels (MD = - 8.02 mg/dL; 95% CI: -13.95 to - 2.09). Meta-regression analyses identified study design as a significant predictor of TG and LDL changes. NLCR was associated with a significant reduction in TG levels among patients with CVD, while changes in TC, LDL-C, and HDL-C were not statistically significant. Subgroup and meta-regression analyses suggested that study design and follow-up duration may influence lipid outcomes. Further high-quality RCTs with longer follow-up are needed to confirm these findings and evaluate their long-term clinical implications.